US Edition
News from Stockhead
We’ve assigned a rating of Unknown factuality to Stockhead. You can read more about how we’ve determined Stockhead’s credibility and reliability as a news source here: https://ground.news/rating-system.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Stockhead News
Boston, Massachusetts · BostonNEJM-published HOPE-B results show HEMGENIX keeping mean factor IX at 36.1% at year five, with 94% of patients off prophylaxis after a single dose.See the Story
uniQure (QURE) Gene Therapy HEMGENIX Cuts Bleeds 90% in 5-Year HOPE-B Trial Data
67% Center coverage: 18 sources
